Inhibikase Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
    • Scientific Publications
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s & GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Jan 04, 2021 8:01am EST

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer

Dec 28, 2020 10:33am EST

Inhibikase Therapeutics Announces Closing of Initial Public Offering

Dec 22, 2020 6:25pm EST

Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering

Dec 03, 2020 8:30am EST

Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration

Jul 27, 2020 11:28am EDT

Inhibikase Files Registration Statement for Proposed Initial Public Offering

Apr 09, 2019 8:00am EDT

Inhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors

Mar 19, 2019 8:00am EDT

Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson’s Disease

Mar 05, 2019 8:00am EST

Inhibikase Therapeutics Appoints Leading Experts in Parkinson’s Disease to its Scientific Advisory Board

Feb 26, 2019 8:00am EST

Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease

RSS
© 2021 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap